Lv21
170 积分 2024-01-06 加入
Adalimumab for Maintenance of Clinical Response and Remission in Patients With Crohn's Disease: The CHARM Trial
26分钟前
已关闭
ABX464 (Obefazimod) Upregulates miR-124 to Reduce Proinflammatory Markers in Inflammatory Bowel Diseases
3个月前
已完结
ACG Clinical Guideline: Upper Gastrointestinal and Ulcer Bleeding
3个月前
已完结
The value of the physical examination in the diagnosis of anemia. Correlation of the physical findings and the hemoglobin concentration
3个月前
已完结
ECCO Guidelines on Therapeutics in Ulcerative Colitis: Medical Treatment
1年前
已完结
Perianal fistulizing Crohn’s disease: Current perspectives on diagnosis, monitoring and management with a focus on emerging therapies
1年前
已完结
Impact of Obefazimod on Viral Persistence, Inflammation, and Immune Activation in People With Human Immunodeficiency Virus on Suppressive Antiretroviral Therapy
1年前
已完结
Induction and Long-term Follow-up With ABX464 for Moderate-to-severe Ulcerative Colitis: Results of Phase IIa Trial
1年前
已完结
ABX464 (obefazimod) for moderate-to-severe, active ulcerative colitis: a phase 2b, double-blind, randomised, placebo-controlled induction trial and 48 week, open-label extension
1年前
已完结
皖公网安备34019202002308
